Axol Bioscience has acquired the ophthalmology business of Newcells Biotech in a deal that broadens its range of induced ...

Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD Lario Therapeutics has secured $2.4 million in new grant funding from The Michael J Fox Foundation for Parkinson’s Research ...

GSK has secured European Commission approval for Exdensur (depemokimab) to treat severe asthma with type 2 inflammation and ...

Mikrobiomik has become the first organisation in Spain to receive authorisation to prepare and process faecal microbiota for treating Clostridioides difficile infection, following approval of its oral ...

Lundbeck A/S has announced encouraging new data from the intravenous part of its phase 2b PROCEED trial, showing that ...

The European Life Sciences Coalition has been launched in Brussels with the aim of strengthening Europe’s life sciences and ...

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence for durvalumab, ...

Dr Michael Chen, CEO and co‑founder of Nuclera, said: “Scientists are under pressure to progress increasingly complex membrane protein programs faster. By partnering with leadXpro, we can pair ...

Muhunthan Thillai MD, co-founder and CEO, Qureight, commented: “Rebecca’s experience, expertise and people-centric leadership ...

Bioxytran has reported positive results from its completed phase 2 trial of ProLectin‑M, showing rapid and sustained viral clearance in subjects with laboratory‑confirmed acute viral infection. The ...

Enhanced Genomics, the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, has announced that Katerina ...

Breye Therapeutics has reported promising early clinical findings for its lead oral therapy danegaptide, following a presentation at the Angiogenesis, Exudation and Degeneration 2026 symposium.